Abstract： Objective To compare the clinical efficacy and adverse reactions of camrelizumab combined with FOLFOX4 and FOLFOX4 alone in the treatment of patients with advanced primary hepatoma,and to provide a basis for immunotherapy in the treatment of advanced primary hepatoma.Methods A total of 100 patients with advanced primary hepatoma were selected and divided into 2 groups according to the grouping criteria,with 50 cases in each group.The experimental group was treated with camrelizumab combined with FOLFOX4 and the control group was treated with FOLFOX4 alone.The efficacy was evaluated after 4 cycles,and the adverse reactions and quality of life were observed.Results The experimental group had disease control rate as 92.00％,which was 76.00％in the control group.The experimental group had obviously higher disease control rate than the con-trol group(P＜0.05).After treatment,AFP、CEA、CA199、total bilirubin、direct bilirubin、indirect bilirubin,、cholinesterase、ALT、AST、ALP and LDH in the experimental group were significantly better than those in the control group(P＜0.05).There was no significant difference in the incidence of total adverse reactions between 2 groups after treatment(P＞0.05).The KPS score,PS score and QOL score of the experimental group were higher than those of the control group(P＜0.05).Conclusion The clinical efficacy of camrelizumab combined with FOLFOX4 in the treatment of advanced primary hepatoma is better than that of chemo-therapy alone and does not increase the side effects of FOLFOX4.